Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 9/20 | 0.64 |
| ▸ | CACNB1 | Q02641 | 9/20 | 0.64 |
| ▸ | CACNA1B | Q00975 | 8/20 | 0.64 |
| ▸ | CACNA1G | O43497 | 7/20 | 0.64 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.64 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.63 |
| ▸ | GPX4 | P36969 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.52 |
| ▸ | TACR3 | P29371 | 1/20 | 0.52 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10670461 | 0.81 | CACNA2D1 (0.61) | CACNA2D1CACNB1CACNA1BCACNA1GCACNA1C | |
| SCHEMBL2305958 | 0.79 | CACNA2D1 (0.59) | CACNA2D1CACNB1CACNA1BCACNA1GCACNA1C | |
| SCHEMBL4179713 | 0.78 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1GCACNA1C | |
| SCHEMBL5268519 | 0.78 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1GCACNA1C | |
| SCHEMBL5266301 | 0.78 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1GCACNA1C | |
| SCHEMBL7665618 | 0.77 | NPC1 (0.78) | CACNA2D1CACNB1CACNA1BCACNA1GCACNA1C | |
| SCHEMBL13994884 | 0.77 | CACNA1G (0.63) | CACNA2D1CACNB1CACNA1BCACNA1GCACNA1C | |
| SCHEMBL1446803 | 0.74 | NPC1 (0.85) | CACNA2D1CACNB1CACNA1BCACNA1GCACNA1C | |
| SCHEMBL1446552 | 0.74 | NPC1 (0.85) | CACNA2D1CACNB1CACNA1BCACNA1GCACNA1C | |
| SCHEMBL3954648 | 0.74 | CACNA1G (1.00) | CACNA2D1CACNB1CACNA1BCACNA1GCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| EP-1915355-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| WO-2007018459-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1915355-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018459-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306087-A1 | Therapeutic Agents | NLN, BDNF, GAP43 | CACNA2D1 3616/4885CACNB1 2515/4885CACNA1B 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.